Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06172699 · ClinicalTrials.gov registry record
Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study
A clinical trial of Cardiac Arrhythmia and Ablation, sponsored by Abbott Medical Devices.
- Active
- Registry status
- 150
- Enrollment target
- 11
- Study locations
NCT06172699: Active study of Cardiac Arrhythmia and Ablation, sponsored by Abbott Medical Devices.
NCT06172699 is a study of Cardiac Arrhythmia and Ablation that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 150 participants, below the 201-participant average among 12 other Cardiac Arrhythmia trials with a reported enrollment target (25% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06172699, a study of Cardiac Arrhythmia and Ablation, is active but no longer recruiting, sponsored by Abbott Medical Devices.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a prospective, non-randomized, multi-center, real-world post-market study to collect and evaluate data regarding the performance of the enhanced atrial fibrillation detection algorithm of the Assert-IQTM Implantable Cardiac Monitor (ICM) device.
Primary Outcome
Episode-based AF detection performance metrics of the Assert-IQTM ICM device compared to that of simultaneous Holter monitoring in 150 subjects who had received the Assert-IQTM ICM device as part of their standard of care.
Conditions Studied
Interventions
- DEVICE Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device
Study Locations (11)
Texas
- Shannon Clinic - San Angelo
- Methodist Texsan Hospital - San Antonio
- Heart Rhythm Associates - The Woodlands
California
- University of California at San Diego (UCSD) Medical Center - San Diego
Florida
- Orlando Health - Orlando
Kansas
- Kansas City Cardiac Arrhythmia Research Foundation - Overland Park
Michigan
- Trinity Health-Michigan d/b/a Michigan Heart - Ann Arbor
New York
- St. Peter's Health Partners Medical Associates, PC - Albany
South Carolina
- Trident Medical Center - Charleston
Tennessee
- Erlanger Medical Center - Chattanooga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2025-12-24 |
What the registry record for NCT06172699 still lists
NCT06172699 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 201-participant average among 12 other Cardiac Arrhythmia trials with a reported enrollment target (25% lower).
The record links to 4 conditions, with Cardiac Arrhythmia appearing as the primary indexed condition, and to 1 intervention - of which Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device is the first listed.
NCT06172699 lists 11 locations in 9 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06172699 about?
NCT06172699 is a clinical study titled "Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study". This is a prospective, non-randomized, multi-center, real-world post-market study to collect and evaluate data regarding the performance of the enhanced atrial fibrillation detection algorithm of the Assert-IQTM Implantable Cardiac Monitor (ICM) device.
What is the current status of trial NCT06172699?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2024-01-01. Estimated completion is 2025-12-24.
What conditions does trial NCT06172699 study?
This clinical trial studies the following conditions: Cardiac Arrhythmia, Ablation, Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent.
What interventions are being tested in trial NCT06172699?
The interventions under investigation include: Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device (DEVICE).
Who is sponsoring clinical trial NCT06172699?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06172699 being conducted?
This trial has 11 study locations across California, Florida, Kansas, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Arrhythmia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06172699's enrollment target sits among peer trials
150 4th of 12 higher than 8 of 12 other Cardiac Arrhythmia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiac Arrhythmia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Validation Study: Extended Wear Performance of the Zio Monitor - SHASTA II
ACTIVE NOT RECRUITING · NA
-
AV Delay Optimization vs. Intrinsic Conduction in Pacemaker Patients With Long PR Intervals
COMPLETED · NA
-
EnSite Precision Observational Study
COMPLETED
-
Evaluating Myocardial Injury for Defibrillation Threshold Testing Methods for ICD Implantation
COMPLETED · NA
-
Measuring Hydration Levels of Healthy and Heart Failure Patients Before, During, and After an Electrophysiology (EP) Procedure
COMPLETED · NA
-
SJM MRI Diagnostic Imaging Registry (IDE)
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI